DURAVYU™ (EYP-1901)
Wet Age-related Macular Degeneration (AMD)
Key Facts
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is strategically focused on developing and commercializing innovative, sustained-release therapeutics to address the high treatment burden in serious retinal diseases. Its lead candidate, DURAVYU™ (EYP-1901), a vorolanib-loaded insert, is advancing through pivotal Phase 3 trials for wet AMD and diabetic macular edema (DME), with key data readouts expected in 2026. The company leverages its proprietary, clinically validated Durasert E™ bioerodible delivery platform to create durable treatments that aim to improve patient outcomes and compliance while capturing significant market opportunity.
View full company profileAbout EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is strategically focused on developing and commercializing innovative, sustained-release therapeutics to address the high treatment burden in serious retinal diseases. Its lead candidate, DURAVYU™ (EYP-1901), a vorolanib-loaded insert, is advancing through pivotal Phase 3 trials for wet AMD and diabetic macular edema (DME), with key data readouts expected in 2026. The company leverages its proprietary, clinically validated Durasert E™ bioerodible delivery platform to create durable treatments that aim to improve patient outcomes and compliance while capturing significant market opportunity.
View full company profileTherapeutic Areas
Other Wet Age-related Macular Degeneration (AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CLS-AX (axitinib injectable suspension) | Clearside Biomedical | Phase 3 Ready |
| Sozinibercept (OPT-302) | Opthea | Phase 2b/3 |
| RGX-314 | REGENXBIO | Phase II |
| ABBV-RGX-314 | REGENXBIO | Phase III |